Clinical Trial Update: The Efficacy and Safety of PRC-063 in Adult ADHD Patients [Phase 3]

View source ↗

Summary

Phase 3 trial update on PRC-063 for adult ADHD reported completed status with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• PRC-063 (PRC-063)

Snippet

Sponsor: Rhodes Pharmaceuticals, L.P. | Conditions: ADHD | Phase 3 | Status: COMPLETED | Results posted: 2019-05-07